<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Mol Hepatol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Mol Hepatol</journal-id><journal-id journal-id-type="publisher-id">CMH</journal-id><journal-title-group><journal-title>Clinical and Molecular Hepatology</journal-title></journal-title-group><issn pub-type="ppub">2287-2728</issn><issn pub-type="epub">2287-285X</issn><publisher><publisher-name>The Korean Association for the Study of the Liver</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4493353</article-id><article-id pub-id-type="doi">10.3350/cmh.2015.21.2.115</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Woo</surname><given-names>Hyun Young</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Heo</surname><given-names>Jeong</given-names></name><xref ref-type="aff" rid="A1"/></contrib></contrib-group><aff id="A1">Department of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Pusan National University Hospital, Busan, Korea.</aff><author-notes><corresp>Corresponding author: Jeong Heo. Department of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Pusan National University Hospital, 179 Gudeok-ro, Seo-gu, Busan 602-739, Korea. Tel: +82-51-240-7869, Fax: +82-51-244-8180, <email>jheo@pusan.ac.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>26</day><month>6</month><year>2015</year></pub-date><volume>21</volume><issue>2</issue><fpage>115</fpage><lpage>121</lpage><history><date date-type="received"><day>06</day><month>2</month><year>2015</year></date><date date-type="accepted"><day>17</day><month>5</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#169; 2015 by The Korean Association for the Study of the Liver</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Despite advances in the treatment of hepatocellular carcinoma (HCC), managing HCC with portal vein thrombosis (PVT) remains challenging. PVT is present in 10-40% of HCC cases at the time of diagnosis and its therapeutic options are very limited. Current guidelines mainly recommend sorafenib for advanced HCC with PVT, but surgery, transarterial chemoemolization, external radiation therapy, radioembolization, transarterial infusion chemotherapy, and combination therapy are also still used. Furthermore, several new emerging therapies such as the administration of immunotherapeutic agents and oncolytic viruses are under investigation. This comprehensive literature review presents current and future management options with their relative advantages and disadvantages and summary data on overall survival.</p></abstract><kwd-group><kwd>Management</kwd><kwd>Hepatocellular carcinoma</kwd><kwd>Portal vein thrombosis</kwd></kwd-group><funding-group><award-group><funding-source country="KR">Pusan National University</funding-source></award-group></funding-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer, and the third most common cause of cancer-related death worldwide.<xref rid="B1" ref-type="bibr">1</xref> It is responsible for over 600,000 deaths annually.<xref rid="B2" ref-type="bibr">2</xref> When patients with HCC have been detected early, curative treatment such as resection and percutaneous ablation are feasible. However, approximately 10-40% patients with HCC have portal vein thrombosis (PVT) at the time of diagnosis.<xref rid="B3" ref-type="bibr">3</xref><xref rid="B4" ref-type="bibr">4</xref> Overall survival have been reported to be much shorter in patients with PVT, compared to patients without PVT, because these patients have more chances to have metastatic disease at diagnosis and fewer therapeutic options. Reported overall survival ranged from 2-4 months in patients with PVT treated with supportive care, compared to 10-24 months in HCC patients without PVT.<xref rid="B4" ref-type="bibr">4</xref><xref rid="B5" ref-type="bibr">5</xref> If thrombus involved the main portal vein, the prognosis would be much worse than in case of thrombus involving a branch portal vein.<xref rid="B6" ref-type="bibr">6</xref></p><p>For decisions regarding initial treatments, the Barcelona Clinic Liver Cancer (BCLC) staging system from Western guidelines is frequently applied.<xref rid="B7" ref-type="bibr">7</xref><xref rid="B8" ref-type="bibr">8</xref> In this system, management options for HCC with PVT are more limited than for HCC without PVT. As three-quarters of HCC cases occur in East Asia, the experiences and data in this area should have been substantially accumulated, so this article aim to review the current status and future prospect of the management of HCC with PVT (<xref ref-type="table" rid="T1">Table 1</xref>).</p></sec><sec><title>SURGICAL MANAGEMENT</title><p>Liver resection produces the best prognosis when it involves only one or two small tumors. Surgical resection for PVT generally resulted in poorer outcomes. Surgical resection for HCC with PVT is more frequently employed across Asia.<xref rid="B9" ref-type="bibr">9</xref> Overall median survival for patients with portal vein invasion ranged from 9 to 33 months according to the degree of portal vein invasion.<xref rid="B6" ref-type="bibr">6</xref> In a study of 438 PVT patients who underwent resection for PVT,<xref rid="B10" ref-type="bibr">10</xref> overall survival was 18.8 months with branch portal invasion and 10.1 months with main portal invasion. In general, outcomes of surgical resection for tumors involving the main portal vein remain relatively poor (median survival, 9-10 months; and 3-year survival rates, 0-6%).<xref rid="B10" ref-type="bibr">10</xref> The main problem of liver resection is that it is often technically infeasible in patients with PVT. The operative mortality rates is 0-6%.</p></sec><sec><title>TRANSARTERIAL CHEMOEMBOLIZATION</title><p>Transarterial chemoembolization (TACE) is widely used as a first-line treatment for unresectable HCC<xref rid="B11" ref-type="bibr">11</xref><xref rid="B12" ref-type="bibr">12</xref><xref rid="B13" ref-type="bibr">13</xref> and is recommended for patients with BCLC stage B, multinodular asymptomatic tumors, and without vascular invasion or extrahepatic spread. A study of the survival benefits of TACE found that the survival time was longer for intermediate-stage patients (BCLC stage B) treated with TACE (median survival, 19-20 months) than for untreated intermediate-stage controls (median survival, 16 months).<xref rid="B14" ref-type="bibr">14</xref><xref rid="B15" ref-type="bibr">15</xref></p><p>Indications for TACE are the absence of vascular invasion and extrahepatic spread, a preserved underlying liver function (mostly Child-Pugh class A or B7 without ascites), and asymptomatic multinodular tumors.<xref rid="B16" ref-type="bibr">16</xref><xref rid="B17" ref-type="bibr">17</xref> Since performing TACE on patients with portal vein invasion or advanced liver failure causes serious complications due to ischemic events in the liver, chemoembolization is not recommended for the patients with decompensated liver cirrhosis, advanced liver dysfunction (Child-Pugh class C), macroscopic invasion, and extrahepatic spread.</p><p>However, in some patients with compensated liver function, TACE can be performed safely with superselective method and is associated with improved overall survival compared to supportive care.<xref rid="B18" ref-type="bibr">18</xref><xref rid="B19" ref-type="bibr">19</xref><xref rid="B20" ref-type="bibr">20</xref> In recent two large meta-analysis.<xref rid="B21" ref-type="bibr">21</xref><xref rid="B22" ref-type="bibr">22</xref> TACE was favored over supportive care for HCC with main as well as branch portal vein tumor thrombus. Overall survival among PVT patients treated with TACE in these studies ranged from 7.0 to 10.2 months. Notably, median survival after TACE prolonged as much as 22-30 months when a tumor is nodular and restricted to 1 lobe or 1-2 segments and hepatic function is preserved, even in the presence of main portal vein tumor thrombosis.<xref rid="B23" ref-type="bibr">23</xref></p><p>Therefore, TACE is considered to be a one of therapeutic option for selected patients with PVT, if their underlying liver function is favorable and the procedure is technically possible. However, reported overall survival of 7.4 to 10.2 months is not significantly better than systemic sorafenib.</p></sec><sec><title>EXTERNAL RADIATION THERAPY</title><p>External radiation therapy for liver lesions has not been broadly performed in patients with compromised underlying liver function due to risk of radiation-induced liver disease.<xref rid="B24" ref-type="bibr">24</xref> However, with advanced of newer techniques, in the form of stereotactic body radiation therapy, high doses of radiation can be delivered very selectively, with relative sparing of non-tumorous liver parenchyma.<xref rid="B25" ref-type="bibr">25</xref></p><p>The effect of external radiation therapy in HCC with PVT has not been well studied and the use of external radiation therapy for HCC is not yet regarded as standard treatment, but remains an area of active investigation. The median survival was shown to be 9.2 months in a large multicenter study in Korea of 994 HCC patients with portal vein tumor thrombosis.<xref rid="B26" ref-type="bibr">26</xref> Studies from Japan and China also reported that overall survival in patients receiving radiotherapy was 10.9 months and 12.3 months and it is significantly better than in patients receiving sorafenib (4.8 months, <italic>P</italic>=0.025) or undergoing surgery (10.3 months, <italic>P</italic>=0.029).<xref rid="B27" ref-type="bibr">27</xref><xref rid="B28" ref-type="bibr">28</xref> In other studies, when external radiation therapy is combined with other modalities such as sorafenib or TACE , overall survival was reported to be 10 months or more.<xref rid="B29" ref-type="bibr">29</xref><xref rid="B30" ref-type="bibr">30</xref> Although these data of radiotherapy in advanced HCC, radiotherapy has not been incorporated into the international guidelines for HCC because of lack of prospective randomized trial. Therefore, there are urgent needs for well-designed randomized controlled studies.</p></sec><sec><title>RADIOEMBOLIZATION</title><p>Radioembolization involves injection of <sup>131</sup>I-labeld lipiodol<xref rid="B31" ref-type="bibr">31</xref> or glass microspheres containing an isotope into the hepatic artery. The most widely used istotope is yttrium-90 (90Y),<xref rid="B32" ref-type="bibr">32</xref><xref rid="B33" ref-type="bibr">33</xref><xref rid="B34" ref-type="bibr">34</xref> it emits pure, high-energy &#946; particles, has a half-life of 2.67 days, and an average penetration power of 2.5 mm (maximum, 11 mm). Resin or glass microspheres with a diameter of 35 &#181;m are used to transport the 90Y. The injected microspheres minimize the thrombotic effect in the artery and are distributed in high concentrations in hypervascular HCC tumors, displaying a radiation-induced antitumor effect. Nuclear medical examination using technetium-99m microaggregated albumin is required in advance of the radioembolization procedure to determine the treatment locations, the required dose of radiation, and measure the risk and degree of exposure to organs other than the target (i.e., the liver).</p><p>90Y has been mainly studied as a locoregional therapy for unresectable HCC that is not amenable to TACE because of diffuse or multifocal disease, or as an alternative to TACE.<xref rid="B6" ref-type="bibr">6</xref> The efficacy of 90Y in patients with HCC who had PVT could be found in subgroup analysis from the three largest series of HCC patients treated with 90Y. In these series, patients who had PVT demonstrated remarkably similar overall survival times ranging from 10.0 to 10.4 months among all patients with PVT.<xref rid="B33" ref-type="bibr">33</xref><xref rid="B34" ref-type="bibr">34</xref><xref rid="B35" ref-type="bibr">35</xref> One of these studies reported that overall survival was 16.6 months among Child-Pugh A cirrhotics with branch PVT and it was decreased to 4.5 months among Child-B cirrhotics with main PVT. Smaller series of patients with PVT treated with 90Y have reported overall survival ranging from 7.2 to 13 months.<xref rid="B36" ref-type="bibr">36</xref> In another small nonrandomized study, among patients with major vascular invasion, the 90Y group showed an overall survival of 12.0 months, compared to 8.0 months in the TACE group.</p><p>In addition, in term of safety, patients receiving radioembolization needed less hospitalization and fewer treatments. Fewer treatment sessions should improve quality of life and reduce the possibility of liver derangement; therefore, in these respects, radioembolization is considered better than conventional TACE and another option for patients with PVT.</p></sec><sec><title>CYTOTOXIC CHEMOTHERAPY</title><p>Cytotoxic chemotherapy has known to be not effective through most clinical trials to date.<xref rid="B37" ref-type="bibr">37</xref><xref rid="B38" ref-type="bibr">38</xref> It is because delayed metabolism of chemotherapeutic agents in the presence of liver cirrhosis may enhance their toxicity and HCC is relatively chemo-resistant to most cytotoxic anticancer drugs.<xref rid="B39" ref-type="bibr">39</xref> Instead, Hepatic arterial infusion chemotherapy (HAIC) has been investigated for treatment of advanced HCC with portal vein tumor thrombosis in Asian countries. <xref rid="B40" ref-type="bibr">40</xref><xref rid="B41" ref-type="bibr">41</xref> In HAIC, chemotherapeutic agent is infused into the hepatic artery <italic>via</italic> an implanted catheter, which reduces systemic side effects by first pass effects and maximizes drug delivery to the tumor. Furthermore, HAIC does not use embolic material, therefore the presence of tumor thrombus may not aggravate ischemic injuries after TACE. In clinical data on HAIC, low dose or high dose of cisplatin and 5-fluorouracil was mainly used as chemotherapeutic agents and the effect of HAIC was compared to systemic chemotherapy or supportive care or sorafenib. In those studies, HAIC showed survival benefit compared to other treatments modalities (median survival 6-7 months versus 5.5, 4 and 2 months in sorafenib, systemic chemotherapy and supportive care, respectively).<xref rid="B42" ref-type="bibr">42</xref><xref rid="B43" ref-type="bibr">43</xref> Although there are no well-designed prospective studies to demonstrate these results, HAIC can be an alternative therapy for patients with portal vein tumor thrombosis, especially in case that patients with advanced HCC do not respond or are intolerant to standard therapy.</p></sec><sec><title>MOLECULAR TARGET THERAPY</title><p>Sorafenib is the multi-tyrosine-kinase inhibitor that targets vascular endothelial growth factor receptor 2, platelet-derived growth factor receptor, and the Raf-1 and c-kit receptors. Sorafenib was the first ever molecularly targeted agent confirmed for the treatment of HCC. In a phase III, multicenter, randomized controlled trial (RCT) conducted on a Western population,<xref rid="B44" ref-type="bibr">44</xref> the median survival period of patients with progressive HCC with hepatic portal invasion and extrahepatic spread who were treated with sorafenib was 10.7 months, which was significantly higher than the median survival period (7.9 months) of the control group, who were treated with palliative medicine alone (<italic>P</italic>=0.00058). In this study, sorafenib also prolonged the time to tumor progression (TTP; 5.5 months and 2.8 months for the sorafenib-treated and control groups, respectively). In a subgroup analysis,<xref rid="B45" ref-type="bibr">45</xref> patients with macroscopic vascular invasion, presumably largely consisting of PVT, had an overall survival of 8.1 months in the sorafenib group, compared to 4.9 in the control group. The respective times to progression were 4.1 and 2.7 months. In a phase III, RCT conducted in Pacific Asia by the Asian Pacific Association for the Study of the Liver, the median survival period of patients with progressive HCC who were treated with sorafenib was 6.5 months, which was again significantly higher than that of the control group (4.2 months; hazard ratio, 0.68; 95% confidence interval, 0.50-0.93; <italic>P</italic>=0.014).<xref rid="B46" ref-type="bibr">46</xref> In subgroup analyses,<xref rid="B47" ref-type="bibr">47</xref> sorafenib was found to have modestly prolonged survival in patients with macroscopic vascular invasion and/or extrahepatic spread of tumor (5.6 months <italic>vs</italic> 4.1 months). TTP was likewise somewhat prolonged (2.7 months <italic>vs</italic>. 1.2 months). The most frequent adverse reactions to sorafenib are hand-foot skin reaction, diarrhea, and fatigue, which occur during the treatment in 40% of patients and it may necessitate dose reduction or discontinuation in a minority of patients.</p><p>Sorafenib is considered as a standard treatment for patients with unresectable HCC whose liver function was well-compensated (Child-Pugh A). Several studies reported that a portion of Child-Pugh B also may show survival benefit from sorafenib treatment.<xref rid="B48" ref-type="bibr">48</xref></p><p>The main problem of sorafenib is that, although a select group of patients showed excellent response to sorafenib,<xref rid="B49" ref-type="bibr">49</xref><xref rid="B50" ref-type="bibr">50</xref> the majority of patients with PVT have shown just modest response and survival. Therefore, there are continued efforts to improve the efficacy of sorafenib. First, combination of sorafenib with locoregional therapies remains an area of active investigation. Second, newer agents were evaluated in clinical trials.</p></sec><sec><title>COMBINATION THERAPY</title><sec><title>Sorafenib combined with TACE</title><p>In studies comparing TACE plus sorafenib and sorafenib alone, overall survival and time to progression (TTP) was significantly longer in combination group than sorafenib alone group (median survival, 8.9 and 5.9 months, respectively; <italic>P</italic>=0.009) (TTP, 2.5 and 2.1 months, respectively; <italic>P</italic>=0.008).<xref rid="B51" ref-type="bibr">51</xref> Another study also showed that the efficacy of TACE plus sorafenib is more superior than TACE alone in advanced stage HCC patients in terms of overall survival and TTP (overall survival, 7.0 and 4.9 months, respectively; <italic>P</italic>=0.003) (TTP, 2.6 and 1.9 mo, respectively; <italic>P</italic>=0.001).<xref rid="B52" ref-type="bibr">52</xref> A phase II study which combined drug eluting bead TACE with sorafenib showed objective response rate of 58% and disease control rate of 100% in advanced HCC patients.<xref rid="B53" ref-type="bibr">53</xref> These data showed that the combination is a promising HCC treatment strategy, but its benefits compared with monotherapy needs to be confirmed in a prospective randomized trial.</p></sec><sec><title>Sorafenib combined with radiotherapy</title><p>The combination treatment using sorafenib and radiotherapy are thought to be synergistic because in vitro and in vivo experiment showed sorafenib enhance the radiosensitivity of human HCC cell lines by inhibiting radiation-induced activation of vascular endothelial growth factor receptors (VEGFRs), a downstream kinase (extracellular signal regulated kinase), and nuclear factor-&#954;B and by increasing radiation-induced apoptosis.<xref rid="B54" ref-type="bibr">54</xref> In a multicenter phase II study in which sorafenib was administered after radioembolization, the median overall survival time was 8.6 months in patients with advanced stage HCC<xref rid="B55" ref-type="bibr">55</xref> Considering the median survival of phase III Asian-Pacific trial data of sorafenib was 6.5 months in advanced HCC, the data of radioembolization plus sorafenib combination therapy seems to be favorable.<xref rid="B46" ref-type="bibr">46</xref> About data of sorafenib plus external beam radiation, a phase II study of sorafenib therapy plus external beam radiation reported an initial complete or partial response rate of 55% and a 2-year overall survival rate of 32% in 40 Taiwanese patients with advanced HCC.<xref rid="B56" ref-type="bibr">56</xref> These results are promising but further research would be needed.</p></sec><sec><title>Emerging therapy</title><p>Besides sorafenib, several newer molecular target agents are investigated but so far none of these drug such as sunitinib, brivanib, linifanib, or the combination of sorafenib and erlotinib have demonstrated efficacy in phase III trials, either in the setting of progression on sorafenib or as primary therapy.<xref rid="B57" ref-type="bibr">57</xref> However, recent two trials showed encouraging results in subgroup analysis. In a phase 2 study about tivanitinib, MET inhibitor, progression free survival was significantly improved compared to placebo (Hazard radio, 0.64, 90% confidence interval, 0.43-0.94; <italic>P</italic>=0.04) and patients with high MET expression had showed substantial benefit from tivanitinib in terms of median overall survival (7.2 months vs. 3.8 months, <italic>P</italic>=0.01).<xref rid="B58" ref-type="bibr">58</xref> Furthermore, in a phase 3 trial of the vascular endothelial growth factor receptor-2 antibody, ramucirumab, median survival was significantly improved in patients with baseline alpha-fetoprotein more than 400 ng/mL. The efficacy of these agents will be investigated in further study.</p><p>Moreover, immunotherapeutic agent such as checkpoint inhibitor (CTLA-4 antibody, programmed cell death receptor-1 blocking antibody) and oncolytic viruses are another promising agent because HCC showed immunologic response spontaneously or to adoptive immunotherapy. Phase I trial (NCT01853618) for tremelimumab (CTLA-4 antibody) and phase I/2 trial (NCT01658878) for nivolumab (programmed cell death receptor-1 blocking antibody) are currently undertaken. Oncolytic viruses are also promising agent because these viruses preferentially replicated in cancer cells as well as final kill the cancer cells.<xref rid="B59" ref-type="bibr">59</xref> In HCC, several oncolytic viruses have been investigated and JX-594 is currently leading agent among these viruses.<xref rid="B60" ref-type="bibr">60</xref> JX-594 is a genetically engineered vaccinia virus and its action mechanism is to induce virus replication-dependent lysis of tumor cells as well as to induce tumor specific immunity. In phase 2 clinical trial of JX-594, high dose of JX-594 showed overall survival about 14.1 months in advanced HCC.<xref rid="B61" ref-type="bibr">61</xref> Further study of this virus are under investigation in advanced HCC.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>Despite recent progress in the treatments for HCC, treatment for patients with PVT remain still as challenging area. Current clinical guideline recommend sorafenib only. However, besides sorafenib, various therapies including surgery, TACE, external radiation therapy, HAIC and radioembolizaiton may be management options in selected patients and the usefulness of combination treatment need to be verified. Newer therapeutic options such as such as immunotherapeutic agent and oncolytic virus are under investigation.</p></sec></body><back><ack><title>Acknowledgements</title><p>This work was supported for 2 years by a Pusan National University Research Grant.</p></ack><fn-group><fn fn-type="conflict"><p><bold>Conflicts of Interest:</bold> The authors have no conflicts to disclose.</p></fn></fn-group><glossary><title>Abbreviations</title><def-list><def-item><term>BCLC</term><def><p>Barcelona Clinic Liver Cancer</p></def></def-item><def-item><term>HAIC</term><def><p>Hepatic arterial infusion chemotherapy</p></def></def-item><def-item><term>HCC</term><def><p>hepatocellular carcinoma</p></def></def-item><def-item><term>PVT</term><def><p>portal vein thrombosis</p></def></def-item><def-item><term>RCT</term><def><p>randomized controlled trial</p></def></def-item><def-item><term>TACE</term><def><p>Transarterial chemoembolization</p></def></def-item><def-item><term>TTP</term><def><p>time to progression</p></def></def-item><def-item><term>VEGFRs</term><def><p>Vascular endothelial growth factor receptors</p></def></def-item><def-item><term>90Y</term><def><p>yttrium-90</p></def></def-item></def-list></glossary><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forner</surname><given-names>A</given-names></name><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Bruix</surname><given-names>J</given-names></name></person-group><article-title>Hepatocellular carcinoma</article-title><source>Lancet</source><year>2012</year><volume>379</volume><fpage>1245</fpage><lpage>1255</lpage><pub-id pub-id-type="pmid">22353262</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>JD</given-names></name><name><surname>Roberts</surname><given-names>LR</given-names></name></person-group><article-title>Hepatocellular carcinoma: a global view</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2010</year><volume>7</volume><fpage>448</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">20628345</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>TK</given-names></name><name><surname>Lai</surname><given-names>CL</given-names></name><name><surname>Wong</surname><given-names>BCY</given-names></name><name><surname>Fung</surname><given-names>J</given-names></name><name><surname>Yuen</surname><given-names>MF</given-names></name></person-group><article-title>Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong</article-title><source>Aliment Pharmacol Ther</source><year>2006</year><volume>24</volume><fpage>573</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">16907890</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Bustamante</surname><given-names>J</given-names></name><name><surname>Castells</surname><given-names>A</given-names></name><name><surname>Vilana</surname><given-names>R</given-names></name><name><surname>Ayuso</surname><given-names>MDC</given-names></name><name><surname>Sala</surname><given-names>M</given-names></name><etal/></person-group><article-title>Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials</article-title><source>Hepatology</source><year>1999</year><volume>29</volume><fpage>62</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">9862851</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#246;niger-Hekele</surname><given-names>M</given-names></name><name><surname>M&#252;ller</surname><given-names>C</given-names></name><name><surname>Kutilek</surname><given-names>M</given-names></name><name><surname>Oesterreicher</surname><given-names>C</given-names></name><name><surname>Ferenci</surname><given-names>P</given-names></name><name><surname>Gangl</surname><given-names>A</given-names></name></person-group><article-title>Hepatocellular carcinoma in Central Europe: prognostic features and survival</article-title><source>Gut</source><year>2001</year><volume>48</volume><fpage>103</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">11115830</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>WY</given-names></name><name><surname>Sangro</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>PJ</given-names></name><name><surname>Cheng</surname><given-names>SQ</given-names></name><name><surname>Chow</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90</article-title><source>Oncology</source><year>2013</year><volume>84</volume><fpage>311</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">23615394</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><collab>European Association For The Study Of The Liver</collab><collab>European Organisation For Research And Treatment Of Cancer</collab><article-title>EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma</article-title><source>J Hepatol</source><year>2012</year><volume>56</volume><fpage>908</fpage><lpage>943</lpage><pub-id pub-id-type="pmid">22424438</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruix</surname><given-names>J</given-names></name><name><surname>Sherman</surname><given-names>M</given-names></name></person-group><article-title>Management of hepatocellular carcinoma: An update</article-title><source>Hepatology</source><year>2011</year><volume>53</volume><fpage>1020</fpage><lpage>1022</lpage><pub-id pub-id-type="pmid">21374666</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omata</surname><given-names>M</given-names></name><name><surname>Lesmana</surname><given-names>L</given-names></name><name><surname>Tateishi</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>PJ</given-names></name><name><surname>Lin</surname><given-names>SM</given-names></name><name><surname>Yoshida</surname><given-names>H</given-names></name><etal/></person-group><article-title>Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma</article-title><source>Hepatol Int</source><year>2010</year><volume>4</volume><fpage>439</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">20827404</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>XP</given-names></name><name><surname>Qiu</surname><given-names>FZ</given-names></name><name><surname>Wu</surname><given-names>ZD</given-names></name><name><surname>Zhang</surname><given-names>ZW</given-names></name><name><surname>Huang</surname><given-names>ZY</given-names></name><name><surname>Chen</surname><given-names>YF</given-names></name><etal/></person-group><article-title>Effects of Location and Extension of Portal Vein Tumor Thrombus on Long-Term Outcomes of Surgical Treatment for Hepatocellular Carcinoma</article-title><source>Ann Surg Oncol</source><year>2006</year><volume>13</volume><fpage>940</fpage><lpage>946</lpage><pub-id pub-id-type="pmid">16788755</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arii</surname><given-names>S</given-names></name><name><surname>Yamaoka</surname><given-names>Y</given-names></name><name><surname>Futagawa</surname><given-names>S</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Kojiro</surname><given-names>M</given-names></name><etal/></person-group><article-title>Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan</article-title><source>Hepatology</source><year>2000</year><volume>32</volume><fpage>1224</fpage><lpage>1229</lpage><pub-id pub-id-type="pmid">11093728</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takayasu</surname><given-names>K</given-names></name><name><surname>Arii</surname><given-names>S</given-names></name><name><surname>Ikai</surname><given-names>I</given-names></name><name><surname>Omata</surname><given-names>M</given-names></name><name><surname>Okita</surname><given-names>K</given-names></name><name><surname>Ichida</surname><given-names>T</given-names></name><etal/></person-group><article-title>Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients</article-title><source>Gastroenterology</source><year>2006</year><volume>131</volume><fpage>461</fpage><lpage>469</lpage><pub-id pub-id-type="pmid">16890600</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikai</surname><given-names>I</given-names></name><name><surname>Arii</surname><given-names>S</given-names></name><name><surname>Kojiro</surname><given-names>M</given-names></name><name><surname>Ichida</surname><given-names>T</given-names></name><name><surname>Makuuchi</surname><given-names>M</given-names></name><name><surname>Matsuyama</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey</article-title><source>Cancer</source><year>2004</year><volume>101</volume><fpage>796</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">15305412</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Bruix</surname><given-names>J</given-names></name></person-group><article-title>Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival</article-title><source>Hepatology</source><year>2003</year><volume>37</volume><fpage>429</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">12540794</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Bruix</surname><given-names>J</given-names></name></person-group><article-title>Novel advancements in the management of hepatocellular carcinoma in 2008</article-title><source>J Hepatol</source><year>2008</year><volume>48</volume><fpage>S20</fpage><lpage>S37</lpage><pub-id pub-id-type="pmid">18304676</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>CM</given-names></name><name><surname>Ngan</surname><given-names>H</given-names></name><name><surname>Tso</surname><given-names>WK</given-names></name><name><surname>Liu</surname><given-names>CL</given-names></name><name><surname>Lam</surname><given-names>CM</given-names></name><name><surname>Poon</surname><given-names>RTP</given-names></name><etal/></person-group><article-title>Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma</article-title><source>Hepatology</source><year>2002</year><volume>35</volume><fpage>1164</fpage><lpage>1171</lpage><pub-id pub-id-type="pmid">11981766</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruix</surname><given-names>J</given-names></name><name><surname>Sala</surname><given-names>M</given-names></name><name><surname>Llovet</surname><given-names>JM</given-names></name></person-group><article-title>Chemoembolization for hepatocellular carcinoma</article-title><source>Gastroenterology</source><year>2004</year><volume>127</volume><fpage>S179</fpage><lpage>S188</lpage><pub-id pub-id-type="pmid">15508083</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinter</surname><given-names>M</given-names></name><name><surname>Hucke</surname><given-names>F</given-names></name><name><surname>Graziadei</surname><given-names>I</given-names></name><name><surname>Vogel</surname><given-names>W</given-names></name><name><surname>Maieron</surname><given-names>A</given-names></name><name><surname>K&#246;nigsberg</surname><given-names>R</given-names></name><etal/></person-group><article-title>Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib</article-title><source>Radiology</source><year>2012</year><volume>263</volume><fpage>590</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">22438359</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>GE</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>HY</given-names></name><name><surname>Hwang</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Chung</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Transarterial Chemoembolization Can Be Safely Performed in Patients with Hepatocellular Carcinoma Invading the Main Portal Vein and May Improve the Overall Survival</article-title><source>Radiology</source><year>2011</year><volume>258</volume><fpage>627</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">21273524</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>RP</given-names></name><name><surname>Lai</surname><given-names>EH</given-names></name><name><surname>Zhang</surname><given-names>YJ</given-names></name><name><surname>Lau</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>M-S</given-names></name><etal/></person-group><article-title>Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Prospective Comparative Study</article-title><source>Ann Surg Oncol</source><year>2011</year><volume>18</volume><fpage>413</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">20839057</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leng</surname><given-names>JJ</given-names></name><name><surname>Xu</surname><given-names>YZ</given-names></name><name><surname>Dong</surname><given-names>JH</given-names></name></person-group><article-title>Efficacy of transarterial chemoembolization for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis</article-title><source>ANZ J Surg</source><year>2014</year><month>8</month><day>3</day><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>TC</given-names></name><name><surname>Xie</surname><given-names>XY</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yin</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>BH</given-names></name><name><surname>Ren</surname><given-names>ZG</given-names></name></person-group><article-title>Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis</article-title><source>BMC Gastroenterol</source><year>2013</year><volume>13</volume><fpage>60</fpage><pub-id pub-id-type="pmid">23566041</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>JW</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Han</surname><given-names>JK</given-names></name><name><surname>Choi</surname><given-names>BI</given-names></name><name><surname>Han</surname><given-names>MC</given-names></name></person-group><article-title>Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization</article-title><source>AJR Am J Roentgenol</source><year>1995</year><volume>165</volume><fpage>315</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">7618547</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>LA</given-names></name><name><surname>Ten Haken</surname><given-names>RK</given-names></name></person-group><article-title>Partial Volume Tolerance of the Liver to Radiation</article-title><source>Semin Radiat Oncol</source><year>2005</year><volume>15</volume><fpage>279</fpage><lpage>283</lpage><pub-id pub-id-type="pmid">16183482</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Zeng</surname><given-names>ZC</given-names></name></person-group><article-title>Is It Time to Adopt External Beam Radiotherapy in the NCCN Guidelines as a Therapeutic Strategy for Intermediate/Advanced Hepatocellular Carcinoma?</article-title><source>Oncology</source><year>2013</year><volume>84</volume><issue>suppl 1</issue><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">23428862</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>JI</given-names></name><name><surname>Yoon</surname><given-names>SM</given-names></name><name><surname>Park</surname><given-names>HC</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>TH</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Multicenter Validation Study of a Prognostic Index for Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma</article-title><source>Cancer Res Treat</source><year>2014</year><volume>46</volume><fpage>348</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">25036573</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakazawa</surname><given-names>T</given-names></name><name><surname>Hidaka</surname><given-names>H</given-names></name><name><surname>Shibuya</surname><given-names>A</given-names></name><name><surname>Okuwaki</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Takada</surname><given-names>J</given-names></name><etal/></person-group><article-title>Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis:propensity score analysis</article-title><source>BMC Gastroenterol</source><year>2014</year><volume>14</volume><fpage>84</fpage><pub-id pub-id-type="pmid">24886354</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>QH</given-names></name><name><surname>Li</surname><given-names>AJ</given-names></name><name><surname>Yang</surname><given-names>GM</given-names></name><name><surname>Lai</surname><given-names>EC</given-names></name><name><surname>Zhou</surname><given-names>WP</given-names></name><name><surname>Jiang</surname><given-names>ZH</given-names></name><etal/></person-group><article-title>Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study</article-title><source>World J Surg</source><year>2013</year><volume>37</volume><fpage>1362</fpage><lpage>1370</lpage><pub-id pub-id-type="pmid">23456227</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>CH</given-names></name><name><surname>Jeng</surname><given-names>KS</given-names></name><name><surname>Lin</surname><given-names>CC</given-names></name><name><surname>Chen</surname><given-names>CK</given-names></name><name><surname>Liu</surname><given-names>CY</given-names></name><name><surname>Lin</surname><given-names>CP</given-names></name><etal/></person-group><article-title>Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma</article-title><source>Clin Drug Investig</source><year>2009</year><volume>29</volume><fpage>65</fpage><lpage>71</lpage></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>SU</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>do Y</given-names></name><name><surname>Ahn</surname><given-names>SH</given-names></name><name><surname>Han</surname><given-names>KH</given-names></name><etal/></person-group><article-title>Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis</article-title><source>Cancer Chemother Pharmacol</source><year>2013</year><volume>71</volume><fpage>165</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">23079897</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raoul</surname><given-names>J</given-names></name><name><surname>Guyader</surname><given-names>D</given-names></name><name><surname>Bretagne</surname><given-names>J</given-names></name><name><surname>Heautot</surname><given-names>J</given-names></name><name><surname>Duvauferrier</surname><given-names>R</given-names></name><name><surname>Bourguet</surname><given-names>P</given-names></name><etal/></person-group><article-title>Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma</article-title><source>Hepatology</source><year>1997</year><volume>26</volume><fpage>1156</fpage><lpage>1161</lpage><pub-id pub-id-type="pmid">9362356</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulik</surname><given-names>LM</given-names></name><name><surname>Carr</surname><given-names>BI</given-names></name><name><surname>Mulcahy</surname><given-names>MF</given-names></name><name><surname>Lewandowski</surname><given-names>RJ</given-names></name><name><surname>Atassi</surname><given-names>B</given-names></name><name><surname>Ryu</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis</article-title><source>Hepatology</source><year>2008</year><volume>47</volume><fpage>71</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">18027884</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salem</surname><given-names>R</given-names></name><name><surname>Lewandowski</surname><given-names>RJ</given-names></name><name><surname>Mulcahy</surname><given-names>MF</given-names></name><name><surname>Riaz</surname><given-names>A</given-names></name><name><surname>Ryu</surname><given-names>RK</given-names></name><name><surname>Ibrahim</surname><given-names>S</given-names></name><etal/></person-group><article-title>Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes</article-title><source>Gastroenterology</source><year>2010</year><volume>138</volume><fpage>52</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">19766639</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilgard</surname><given-names>P</given-names></name><name><surname>Hamami</surname><given-names>M</given-names></name><name><surname>Fouly</surname><given-names>AE</given-names></name><name><surname>Scherag</surname><given-names>A</given-names></name><name><surname>M&#252;ller</surname><given-names>S</given-names></name><name><surname>Ertle</surname><given-names>J</given-names></name><etal/></person-group><article-title>Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and longterm survival</article-title><source>Hepatology</source><year>2010</year><volume>52</volume><fpage>1741</fpage><lpage>1749</lpage><pub-id pub-id-type="pmid">21038413</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sangro</surname><given-names>B</given-names></name><name><surname>Carpanese</surname><given-names>L</given-names></name><name><surname>Cianni</surname><given-names>R</given-names></name><name><surname>Golfieri</surname><given-names>R</given-names></name><name><surname>Gasparini</surname><given-names>D</given-names></name><name><surname>Ezziddin</surname><given-names>S</given-names></name><etal/></person-group><article-title>Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation</article-title><source>Hepatology</source><year>2011</year><volume>54</volume><fpage>868</fpage><lpage>878</lpage><pub-id pub-id-type="pmid">21618574</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salem</surname><given-names>R</given-names></name><name><surname>Lewandowski</surname><given-names>R</given-names></name><name><surname>Roberts</surname><given-names>C</given-names></name><name><surname>Goin</surname><given-names>J</given-names></name><name><surname>Thurston</surname><given-names>K</given-names></name><name><surname>Abouljoud</surname><given-names>M</given-names></name><etal/></person-group><article-title>Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis</article-title><source>J Vasc Interv Radiol</source><year>2004</year><volume>15</volume><fpage>335</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">15064336</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeo</surname><given-names>W</given-names></name><name><surname>Mok</surname><given-names>TS</given-names></name><name><surname>Zee</surname><given-names>B</given-names></name><name><surname>Leung</surname><given-names>TW</given-names></name><name><surname>Lai</surname><given-names>PB</given-names></name><name><surname>Lau</surname><given-names>WY</given-names></name><etal/></person-group><article-title>A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma</article-title><source>J Natl Cancer Inst</source><year>2005</year><volume>97</volume><fpage>1532</fpage><lpage>1538</lpage><pub-id pub-id-type="pmid">16234567</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>S</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Lim</surname><given-names>H</given-names></name><name><surname>Cho</surname><given-names>J</given-names></name><etal/></person-group><article-title>Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><fpage>3501</fpage><lpage>3508</lpage><pub-id pub-id-type="pmid">23980077</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>CL</given-names></name><name><surname>Wu</surname><given-names>PC</given-names></name><name><surname>Chan</surname><given-names>GC</given-names></name><name><surname>Lok</surname><given-names>AS</given-names></name><name><surname>Lin</surname><given-names>HJ</given-names></name></person-group><article-title>Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial</article-title><source>Cancer</source><year>1988</year><volume>62</volume><fpage>479</fpage><lpage>483</lpage><pub-id pub-id-type="pmid">2839280</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inaba</surname><given-names>Y</given-names></name><name><surname>Arai</surname><given-names>Y</given-names></name><name><surname>Yamaura</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Najima</surname><given-names>M</given-names></name><name><surname>Aramaki</surname><given-names>T</given-names></name><etal/></person-group><article-title>Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301)</article-title><source>Am J Clin Oncol</source><year>2011</year><volume>34</volume><fpage>58</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">20177362</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>SW</given-names></name><name><surname>Jang</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>SG</given-names></name><name><surname>Cha</surname><given-names>SW</given-names></name><etal/></person-group><article-title>The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma</article-title><source>Asia Pac J Clin Oncol</source><year>2012</year><volume>8</volume><fpage>164</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">22524575</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheong</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>KM</given-names></name><name><surname>Cho</surname><given-names>SW</given-names></name><name><surname>Won</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>JK</given-names></name><name><surname>Wang</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Survival benefits of intra-arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis</article-title><source>Hepatol Res</source><year>2005</year><volume>32</volume><fpage>127</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">15869904</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiramine</surname><given-names>Y</given-names></name><name><surname>Uto</surname><given-names>H</given-names></name><name><surname>Imamura</surname><given-names>Y</given-names></name><name><surname>Tabu</surname><given-names>K</given-names></name><name><surname>Baba</surname><given-names>Y</given-names></name><name><surname>Hiwaki</surname><given-names>T</given-names></name><etal/></person-group><article-title>Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study</article-title><source>Exp Ther Med</source><year>2011</year><volume>2</volume><fpage>433</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">22977522</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Ricci</surname><given-names>S</given-names></name><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Hilgard</surname><given-names>P</given-names></name><name><surname>Gane</surname><given-names>E</given-names></name><name><surname>Blanc</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Sorafenib in advanced hepatocellular carcinoma</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>378</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">18650514</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruix</surname><given-names>J</given-names></name><name><surname>Raoul</surname><given-names>JL</given-names></name><name><surname>Sherman</surname><given-names>M</given-names></name><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Bolondi</surname><given-names>L</given-names></name><name><surname>Craxi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial</article-title><source>J Hepatol</source><year>2012</year><volume>57</volume><fpage>821</fpage><lpage>829</lpage><pub-id pub-id-type="pmid">22727733</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Tsao</surname><given-names>CJ</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial</article-title><source>Lancet Oncol</source><year>2009</year><volume>10</volume><fpage>25</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">19095497</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Guan</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Tsao</surname><given-names>CJ</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial</article-title><source>Eur J Cancer</source><year>2012</year><volume>48</volume><fpage>1452</fpage><lpage>1465</lpage><pub-id pub-id-type="pmid">22240282</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozenne</surname><given-names>V</given-names></name><name><surname>Paradis</surname><given-names>V</given-names></name><name><surname>Pernot</surname><given-names>S</given-names></name><name><surname>Castelnau</surname><given-names>C</given-names></name><name><surname>Vullierme</surname><given-names>MP</given-names></name><name><surname>Bouattour</surname><given-names>M</given-names></name><etal/></person-group><article-title>Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib</article-title><source>Eur J Gastroenterol Hepatol</source><year>2010</year><volume>22</volume><fpage>1106</fpage><lpage>1110</lpage><pub-id pub-id-type="pmid">20300004</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbier</surname><given-names>L</given-names></name><name><surname>Muscari</surname><given-names>F</given-names></name><name><surname>Le Guellec</surname><given-names>S</given-names></name><name><surname>Pariente</surname><given-names>A</given-names></name><name><surname>Otal</surname><given-names>P</given-names></name><name><surname>Suc</surname><given-names>B</given-names></name></person-group><article-title>Liver resection after downstaging hepatocellular carcinoma with sorafenib</article-title><source>Int J Hepatol</source><year>2011</year><volume>2011</volume><fpage>791013</fpage><pub-id pub-id-type="pmid">22135750</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>SW</given-names></name><name><surname>Jang</surname><given-names>JY</given-names></name><name><surname>Shim</surname><given-names>KY</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>SG</given-names></name><name><surname>Cha</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis</article-title><source>Gut Liver</source><year>2013</year><volume>7</volume><fpage>696</fpage><lpage>703</lpage><pub-id pub-id-type="pmid">24312711</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>GH</given-names></name><name><surname>Shim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Ryu</surname><given-names>MH</given-names></name><name><surname>Ryoo</surname><given-names>BY</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name><etal/></person-group><article-title>Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses</article-title><source>Radiology</source><year>2013</year><volume>269</volume><fpage>603</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">23864102</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Duan</surname><given-names>Z</given-names></name><name><surname>Long</surname><given-names>X</given-names></name><name><surname>Hertzanu</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e96620</fpage><pub-id pub-id-type="pmid">24817002</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawlik</surname><given-names>TM</given-names></name><name><surname>Reyes</surname><given-names>DK</given-names></name><name><surname>Cosgrove</surname><given-names>D</given-names></name><name><surname>Kamel</surname><given-names>IR</given-names></name><name><surname>Bhagat</surname><given-names>N</given-names></name><name><surname>Geschwind</surname><given-names>JF</given-names></name></person-group><article-title>Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><fpage>3960</fpage><lpage>3967</lpage><pub-id pub-id-type="pmid">21911714</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Gu</surname><given-names>K</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Yuan</surname><given-names>D</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>N</given-names></name><etal/></person-group><article-title>Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo</article-title><source>Cancer Lett</source><year>2013</year><volume>329</volume><fpage>109</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">23142289</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>PK</given-names></name><name><surname>Poon</surname><given-names>DY</given-names></name><name><surname>Khin</surname><given-names>MW</given-names></name><name><surname>Singh</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>HS</given-names></name><name><surname>Goh</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e90909</fpage><pub-id pub-id-type="pmid">24614178</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>SW</given-names></name><name><surname>Lin</surname><given-names>LC</given-names></name><name><surname>Kuo</surname><given-names>YC</given-names></name><name><surname>Liang</surname><given-names>JA</given-names></name><name><surname>Kuo</surname><given-names>CC</given-names></name><name><surname>Chiou</surname><given-names>JF</given-names></name></person-group><article-title>Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2014</year><volume>88</volume><fpage>1041</fpage><lpage>1047</lpage><pub-id pub-id-type="pmid">24661657</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Hernandez-Gea</surname><given-names>V</given-names></name></person-group><article-title>Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design</article-title><source>Clin Cancer Res</source><year>2014</year><volume>20</volume><fpage>2072</fpage><lpage>2079</lpage><pub-id pub-id-type="pmid">24589894</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eathiraj</surname><given-names>S</given-names></name><name><surname>Palma</surname><given-names>R</given-names></name><name><surname>Volckova</surname><given-names>E</given-names></name><name><surname>Hirschi</surname><given-names>M</given-names></name><name><surname>France</surname><given-names>DS</given-names></name><name><surname>Ashwell</surname><given-names>MA</given-names></name><name><surname>Chan</surname><given-names>TC</given-names></name></person-group><article-title>Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>20666</fpage><lpage>20676</lpage><pub-id pub-id-type="pmid">21454604</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melcher</surname><given-names>A</given-names></name><name><surname>Parato</surname><given-names>K</given-names></name><name><surname>Rooney</surname><given-names>CM</given-names></name><name><surname>Bell</surname><given-names>JC</given-names></name></person-group><article-title>Thunder and lightning: immunotherapy and oncolytic viruses collide</article-title><source>Mol Ther</source><year>2011</year><volume>19</volume><fpage>1008</fpage><lpage>1016</lpage><pub-id pub-id-type="pmid">21505424</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heo</surname><given-names>J</given-names></name><name><surname>Breitbach</surname><given-names>CJ</given-names></name><name><surname>Moon</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>CW</given-names></name><name><surname>Patt</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy</article-title><source>Mol Ther</source><year>2011</year><volume>19</volume><fpage>1170</fpage><lpage>1179</lpage><pub-id pub-id-type="pmid">21427706</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heo</surname><given-names>J</given-names></name><name><surname>Reid</surname><given-names>T</given-names></name><name><surname>Ruo</surname><given-names>L</given-names></name><name><surname>Breitbach</surname><given-names>CJ</given-names></name><name><surname>Rose</surname><given-names>S</given-names></name><name><surname>Bloomston</surname><given-names>M</given-names></name><etal/></person-group><article-title>Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer</article-title><source>Nat Med</source><year>2013</year><volume>19</volume><fpage>329</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">23396206</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Summary of management for hepatocellular carcinoma with portal vein thrombosis</title></caption><graphic xlink:href="cmh-21-115-i001"/><table-wrap-foot><fn><p>HAIC, hepatic artery infusion chemotherapy; PVTT, portal vein tumor thrombosis; TACE, transarterial chemoembolization; GI, gastrointestinal.</p></fn></table-wrap-foot></table-wrap></floats-group></article>